EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia

Helga Zoega iD, Michael O Falster iD, Malcolm B Gillies iD, Melisa Litchfield iD, Ximena Camacho iD, Claudia Bruno iD, Benjamin Daniels iD, Natasha Donnolley iD, Alys Havard iD, Andrea L Schaffer iD, Georgina Chambers iD, Louisa Degenhardt iD und 7 weitere

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.5887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Helga Zoega und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Databases, Factual. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Wellcome Trust, Cancer Institute NSW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia.

Results

The platform comprises Medicare‐eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005–2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre‐pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti‐infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).

Conclusion

The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically‐ and policy‐relevant research questions about quality use of medicines and health outcomes in Australia and globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Databases, FactualHumansFemaleMiddle AgedMaleAgedNew South WalesAdultAdolescentYoung AdultCost-Benefit AnalysisHospitalizationPrescription DrugsAged, 80 and overPharmacoepidemiology

Stichwörter der Autor:innen

Australiadata linkagepharmacoepidemiologypopulation‐basedreal‐world data

Substanzen

Prescription Drugs

Autor:innen und Institutionen

  • School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
  • Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland.
  • National Drug and Alcohol Research Centre, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
  • The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
  • Centre for Big Data Research in Health, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
  • The Kirby Institute, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.

ORCID-Profile: Helga Zoega, Michael O Falster, Malcolm B Gillies, Melisa Litchfield, Ximena Camacho, Claudia Bruno, Benjamin Daniels, Natasha Donnolley, Alys Havard, Andrea L Schaffer, Georgina Chambers, Louisa Degenhardt, Timothy Dobbins, Natasa Gisev, Rebecca Ivers, Louisa Jorm, Bette Liu, Claire M Vajdic, Sallie-Anne Pearson

Förderung

  • National Health and Medical Research Council
  • Wellcome Trust
  • Cancer Institute NSW
  • NSW Health
  • University of New South Wales
  • National Heart Foundation of Australia

Zitieren

APA

Zoega, H., Falster, M. O., Gillies, M. B., Litchfield, M., Camacho, X., Bruno, C., Daniels, B., Donnolley, N., Havard, A., Schaffer, A. L., Chambers, G., Degenhardt, L., Dobbins, T., Gisev, N., Ivers, R., Jorm, L., Liu, B., Vajdic, C. M., & Pearson, S. A. (2024). The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5887

Vancouver

Zoega H, Falster MO, Gillies MB, Litchfield M, Camacho X, Bruno C, et al. The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5887

BibTeX
@article{Zoega2024,
  author = {Zoega, Helga and Falster, Michael O and Gillies, Malcolm B and Litchfield, Melisa and Camacho, Ximena and Bruno, Claudia and Daniels, Benjamin and Donnolley, Natasha and Havard, Alys and Schaffer, Andrea L and Chambers, Georgina and Degenhardt, Louisa and Dobbins, Timothy and Gisev, Natasa and Ivers, Rebecca and Jorm, Louisa and Liu, Bette and Vajdic, Claire M and Pearson, Sallie-Anne},
  title = {The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.5887}
}
Kostenlos starten →